Please enable JavaScript.

Coggle requires JavaScript to display documents.

Patient (Trazodone (Pharmacokinetics (Dosage (Depression (Immediate…

- - - - Immediate release: 30 to 100 minutes
      - Extended release: 9 hours
    - - 5-9 hours
      - Prolonged in obese patients
    - - Hepatic via CYP3A4 (extensive)
      - To an active metabolite (mCPP)
    - - Depression
        
        Immediate Release: Initial: 150 mg daily in divided doses, Max: 400 - 600 mg daily
        
        Extended Release: Initial: 150 mg once daily at bedtime, Max: 375 mg daily
      - Dementia
        
        Immediate Release: Initial: 25 to 50 mg once daily at bedtime, Max: 300 mg daily
      - Insomnia
        
        Immediate Release: Usual dose: 50 mg to 100 mg at bedtime
    - - Feces ~21%
      - Urine 74%
        
        <1% excreted unchanged
- - - - Not metabolized
    - - Infants 1 month to 12 years: 4.7 hours
      - Adults, normal: 5 to 7 hours; increased half-life with decreased renal function
      - Anuric adult patients: 132 hours
      - Adults during hemodialysis: 3.8 hours
    - - Proportional to renal function
      - Urine as unchanged drug
    - - Postherpetic neuralgia
        
        Immediate release:range: 1,800 to 3,600 mg/day in divided doses
        
        Extended Release: Days ≥15: 1,800 mg once daily
      - Seizures, partial onset
        
        900 to 1,800 mg/day administered in 3 divided doses
- - - - Hepatic, via CYP3A to minimally active metabolites
    - - 2.5 to 4 hours
    - - ~15 hours
    - - HIV-1 Infection Naive: 800 mg coadministered w/ Ritonavir 100 mg once daily
      - Pregnant: 600 mg coadministered w/ Ritonavir 100 mg twice daily
      - HIV-1 nPEP: 800 mg plus ritonavir 100 mg once daily, w/in 72 hours of exposure for 28 days
      - HIV-1 Infection-Experienced: Genotypic testing recommended
    - - Feces ~80%
        
        41% as unchanged drug
      - Urine ~14%
        
        8% as unchanged drug
  - - - Alfuzosin
- - - - Tablets, oral suspension: Immediate release: Mean: 5.2 to 8.1 hours
      - Capsules: Median: 6 hours (range: 3 to 8 hours)
      - Tablets: Controlled release: 6 to 10 hours
    - - Primary metabolites are formed via oxidation and methylation of parent drug
      - Subsequent glucuronide/sulfate conjugation
      - Extensively hepatic via CYP2D6 enzymes
    - - Paxil CR: 15 to 20 hours
      - Pexeva: 33.2 hours
      - Paxil: 21 hours
    - - Feces
        
        36% primarily via bile
        
        <1% as unchanged drug
      - Urine
        
        64%
        
        2% as unchanged drug
    - - Adult: 20 mg once daily, Max: 50-60 mg daily
- - - - Alfuzosin
  - - - Fasted: 2 hours
      - Nonfasted: 4 hours
    - - Hepatic via CYP3A4 and 2D6
      - Five metabolites
      - Low concentration of an active metabolite (M-2) achieved in plasma
    - - Children: 2 to 4 hours
      - Adults: 3 to 5 hours
    - - Feces ~86%
        
        ~34% as unchanged drug
      - Urine ~11%
        
        ~4% as unchanged drug
      - Children 1.5 to 1.7 times faster than adults
    - - HIV-1 Infection: max of 600 mg twice daily
      - HIV-1 nPEP: 100 mg once daily, w/in 72 hours of exposure, for 28 days, w/other retroviral agents
      - Infants >1 month and Children: 250 mg/m2/dose twice daily
- - - - Emtricitabine: 3 hours
      - Tenofovir alafenamide: 1 hour
    - - Emtricitabine: Not significantly metabolized
      - Tenofovir alafenamide: primarily intracellular metabolism; minimal extent by CYP3A
    - - Emtricitabine: 10 hours
      - Tenofovir alafenamide: 0.51 hours
    - - Emtricitabine
        
        Feces 13.7%
        
        Urine 70%
      - Tenofovir alafenamide
        
        Feces 31.7%
        
        Urine <1%
    - - HIV-1 Infection: One tablet (emtricitabine 200 mg/tenofovir alafenamide 25 mg) once daily